Signal
Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by partnering with Evinova and using its AI platform designed to speed up clinical development.
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-02-24 18:12 UTCUpdated 2026-02-25 10:37 UTC
rss
regulationfierce_biotech
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Astellas bets on Vir cancer drug, and other licensing deals Phil.Taylor Wed, 25/02/2026 - 10:37.
Score total
0.97
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Astellas bets on Vir cancer drug, and other licensing deals
pharmaphorum · pharmaphorum.com · 2026-02-25 10:37 UTC
Astellas Pharma and AstraZeneca are joining Bristol Myers Squibb by partnering with Evinova and using its AI platform designed to speed up clinical development.
Fierce Biotech · fiercebiotech.com · 2026-02-24 18:12 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- pharmaphorum.com (1)
- fiercebiotech.com (1)